<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The diagnosis of follicular dendritic cell (<z:chebi fb="17" ids="38848">FDC</z:chebi>) <z:hpo ids='HP_0100242'>sarcoma</z:hpo> can be challenging because of its morphologic overlaps with many other spindle cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and, therefore, new phenotypic markers will be helpful in its differential diagnosis </plain></SENT>
<SENT sid="1" pm="."><plain>Podoplanin is a mucin-type transmembrane <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> that has recently been detected in reactive <z:chebi fb="17" ids="38848">FDCs</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the expression patterns of podoplanin using a new mouse monoclonal antibody D2-40, and compared them with CD21, a well-established <z:chebi fb="17" ids="38848">FDC</z:chebi> marker, in a comprehensive panel of cases </plain></SENT>
<SENT sid="3" pm="."><plain>The panel included 4 FDC <z:hpo ids='HP_0100242'>sarcomas</z:hpo>, 38 spindle cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> of other types, 25 reactive <z:mp ids='MP_0000688'>lymphoid hyperplasia</z:mp>, and 117 lymphoid and 5 myeloid malignant hematopoietic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Our study revealed that D2-40 strongly stained 3 of 4 FDC <z:hpo ids='HP_0100242'>sarcomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, D2-40 stained only 2/38 other spindle cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> tested </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, we observed that D2-40 highlighted more <z:chebi fb="17" ids="38848">FDC</z:chebi> meshworks than CD21 in <z:e sem="disease" ids="C0017531" disease_type="Disease or Syndrome" abbrv="GLNH|AFLH">Castleman's disease</z:e>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nodular lymphocyte predominance Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and residual reactive germinal centers in a variety of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types </plain></SENT>
<SENT sid="7" pm="."><plain>D2-40 and CD21 stained an equal number of cases of reactive <z:mp ids='MP_0000688'>lymphoid hyperplasia</z:mp>, <z:e sem="disease" ids="C1264177" disease_type="Neoplastic Process" abbrv="">progressively transformed germinal centers</z:e> and angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>No expression of podoplanin was detected in <z:mpath ids='MPATH_458'>normal</z:mpath> or neoplastic lymphoid and myeloid cells </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that podoplanin (D2-40) is a sensitive and specific <z:chebi fb="17" ids="38848">FDC</z:chebi> marker, which is superior or equal to CD21 in evaluating both reactive and neoplastic <z:chebi fb="17" ids="38848">FDCs</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, our results suggest that podoplanin (D2-40) can be used to support the diagnosis of <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
</text></document>